325 5. Complicanze precoci Ringraziamenti C.O. ringrazia il professor Fabio Ciceri per l’opportunità di contribuire a questo progetto Handbook del GITMO, lo staff medico ed infermieristico dell’Ematologia ed Unità Trapianto di Midollo dell’Ospedale San Raffaele per la consolidata collaborazione clinica nell’assistenza ai pazienti e la crescita professionale ed umana; infine, la professoressa Malgorzata Mikulska per avermi introdotta nel mondo dell’infettivologia nel paziente ematologico trapiantato, per i preziosi insegnamenti e la sua amicizia. Bibliografia [1] Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. BMT 2021; doi:10.1038/s41409-021-01227-8 [2] Penack O, Peczynski C, Mohty M, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv 2020; doi:10.1182/bloodadvances.2020003418 [3] Styczynski J, Tridello G, Koster L, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. BMT 2020; doi:10.1038/ s41409-019-0624-z [4] Girmenia C, Bertaina A, Piciocchi A, et al. Incidence, risk factors and outcome of pre-engraftment Gram-negative bacteremia after allogenic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey. CID 2017; doi:10.1093/cid/cix690 [5] Forcina A, Baldan R, Marasco V, et al. Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. BMT 2017; doi:10.1038/bmt.2016.234 [6] https://www.ecdc.europa.eu/sites/default/files/documents/ECDC-WHO-AMR-report.pdf [7] Evans L, Rhodes A, Alhazzani W, et al. Executive Summary: Surviving Sepsis Campaign: International guidelines for the management of sepsis and septic shock 2021. Crit Care Med 2021; doi: 10.1097/CCM.0000000000005357 [8] Averbuch D, Tridello G, Hoek J, et al. Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation group. Clinical Infectious Diseases 2017;65(11):1819–28 [9] Averbuch D, Tridello G, Hoek J, et al. Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: risk factors and association with mortality. Journal of Infection 2020;81: 882–894 [10] Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, et al. Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clinical Infectious Diseases 2020;70(6):1068–74 [11] Chumbita M, Puerta-Alcalde P, Gudiol C, et al. Impact of empirical antibiotic regimens on mortality in neutropenic patients with bloodstream infection presenting with septic shock. Antimicrob Agents Chemother 2021; AAC0174421, doi: 10.1128/AAC.01744-21 [12] Albasanz-Puig A, Gudiol C, Puerta-Alcade P, et al. Impact of the inclusion of an aminoglycoside to the initial empirical antibiotic therapy for Gram-negative bloodstream infections in hematological neutropenic patients: a propensity-matched cohort study (AMINOLACTAM study). Antimicrob Agents Chemother 2021; doi: 10.1128/AAC.00045-21 [13] Gudiol C, Albasanz-Puig A, Laporte-Amargós J, et al. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2020; doi: 10.1128/ AAC.02494-19 [14] Albasanz-Puig A, Durà-Miralles X, Laporte-Amargós J, et al. Effect of combination antibiotic empirical therapy on mortality in neutropenic cancer patients with Pseudomonas aeruginosa pneumonia. Microorganisms 2022; doi: 10.3390/microorganisms10040733 [15] Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4° European Conference on Infections in Leukemia. Haematologica 2013; doi: 10.3324/haematol.2013.091025 [16] Tamma PD, Hsu AJ. Defining the role of novel ß-Lactam agents that target carbapenem-resistant Gram-Negative organisms. J Pediatric Infect Dis Soc 2019; doi: 10.1093/jpids/piz002 [17] Chaftari AM, Hachem R, Malek AE, et al. A prospective randomized study comparing ceftolozane/tazobactam to standard of care in the management of neutropenia and fever in patients with hematological malignancies. Open Forum Infect Dis 2022; doi: 10.1093/ofid/ofac079 [18] Bergas A, Albasanz-Puig A, Fernández-Cruz A, et al. Real-life use of ceftolozane/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH Study). Microbiol Spectr 2022; doi: 10.1128/spectrum.02292-21 [19] Verlinden A, Mikulska M, Knelange NS, et al. Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant 2020; doi: 10.1038/s41409-020-0811-y [20] Orasch C, Averbuch D, Mikulska M, et al. Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. Clin Microbiol Infect 2015; doi: 10.1016/j.cmi.2014.10.014 [21] Aguilar-Guisado M, Espigado I, Martín-Pe a A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017; doi: 10.1016/S2352-3026(17)30211-9 [22] Gustinetti G, Raiola AM, Varaldo R, et al. De-Escalation and Discontinuation of Empirical Antibiotic Treatment in a Cohort of Allogeneic Hematopoietic Stem Cell Transplantation Recipients during the Pre-Engraftment Period. Biol Blood Marrow Transplant 2018; 24:1721-1726 [23] de Jonge NA, Sikkens JJ, Zweegman S, et al. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. Lancet Haematol 2022; doi: 10.1016/S2352-3026(22)00145-4.
RkJQdWJsaXNoZXIy ODUzNzk5